Piper Sandler Maintains Overweight on Corcept Therapeutics, Raises Price Target to $88

Benzinga Newsdesk www.benzinga.com Positive 81.1%

Neg 0% Neu 0% Pos 81.1%

Piper Sandler analyst David Amsellem maintains Corcept Therapeutics (NASDAQ:CORT) with a Overweight and raises the price target from $73 to $88.